Evening Dosing of Antihypertensive Therapy to Reduce Cardiovascular Events: A Third Type of Evidence Based on a Systematic Review and Meta-Analysis of Randomized Trials

Journal of Clinical Hypertension

Volumn 16, Issue 8, 2014, Pages 561-568

  Roush, George C ^a   Fapohunda, Jadesola ^a   Kostis, John B ^b  

^a ST VINCENT S MEDICAL CENTER   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; NITRENDIPINE; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; EVIDENCE BASED PRACTICE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; META ANALYSIS; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; AGED; CARDIOVASCULAR DISEASES; CIRCADIAN RHYTHM; COMPLICATION; DOSE RESPONSE; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84905754560     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12354     Document Type: Article

References (28)

1. Veterans Administration. Effects of dosing on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-1034.
2. Veterans Administration. Effects of dosing on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-1152.
3. National Institute for Health and Clinical Excellence. Hypertension: Clinical management of primary hypertension in adults. Newcastle Guideline Development and Research Unit, National Clinical Guideline Center, and the British Hypertension Society, August 2011.
4. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357.
5. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8).JAMA. 2014;311:507-520.
6. Hansen TW, Li Y, Boggia J, et al. Predictive role of the nighttime blood pressure. Hypertension. 2011;57:3-10.
7. The ABC-H Investigators: Roush G, Fagard R, Salles G, Pierdomenico S, Reboldi G, Verdecchia P, Eguchi K, Kario K, Hoshide S, Polognia J, de la Sierra A, Hermida R, Dolan E, Zamalloa H. Prognostic Impact from Clinic, Daytime, and Nighttime Systolic Blood Pressure in 9 Cohorts of 13, 844 Patients with Hypertension. J Hypertension. 2014 (in press).
8. Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of circadian time of hypertension dosing on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010;27:1629-1651.
9. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
10. Hermida RC, Ríos MT, Crespo JJ, et al. Hygia Project Investigators. Dosing-time regimen of hypertension medications significantly affects ambulatory blood pressure and clinical characteristics of patients with resistant hypertension. Chronobiol Int. 2013;30:192-206.
11. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. West Sussex, UK: JohnWiley & Sons; 2009.
12. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534-2544.
13. Black HR, Elliott WJ, Grandits G, et al. CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
14. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
15. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
16. Liu L, Wang JG, Gong L, et al. Comparison of active dosing and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16(12 pt 1):1823-1829.
17. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757-764.
18. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension. 2001;38:E28-E32.
19. Heber ME, Brigden GS, Caruana MP, et al. First dose response and 24-hour antihypertensive efficacy of the new once-daily angiotensin converting enzyme inhibitor, ramipril. Am J Cardiol. 1988;62:239-245.
20. Hermida RC, Ayala DE, Fernandez JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension. 2008;51:69-76.
21. Zhao P, Xu P, Wan C, Wang Z. Evening versus morning dosing regimen drug therapy for hypertension (Review). Cochrane Database Syst Rev. 2011;CD004184.
22. Sachdeva A, Weder AB. Nocturnal sodium excretion, blood pressure dipping, and sodium sensitivity. Hypertension. 2006;48:527-533.
23. Quinaglia T, Martins LC, Figueiredo VN, et al. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens. 2011;25:656-664.
24. Higashi Y, Nakagawa K, Kimura M, et al. Circadian variation of blood pressure and endothelial function in patients with essential hypertension: a comparison of dippers and non-dippers. J Am Coll Cardiol. 2002;40:2039-2043.
25. Lerman A, Zeiher AM. Endothelial dysfunction: cardiovascular events. Circulation. 2005;111:363-368.
26. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37:S14-S80.
27. Hermida RC, Ayala DE, Mojón A, Fernández JR. Role of time-of-day of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk. Chronobiol Int. 2013;30:328-339.
28. Santiago TM, Lopez LM. Nitrendipine: a new dihydropyridine calcium-channel antagonist for the treatment of hypertension. DICP. 1990;24:167-175.